The assessment of visual function is extremely important in evaluating the progression or extent of any eye disease. It is also important in evaluating the effectiveness of any treatment modalities.

Visual function has traditionally been evaluated by assessing visual acuity. Visual acuity, however, is not sensitive enough to quantify human visual function and its impairment in relation to daily life activities.

Morphological analysis by fundus photography, on the other hand, does not allow quantitative evaluation of the “quality” of visual function and therefore it does not allow us to measure changes in retinal functions.

**Use of Standard Perimetry**

Perimetry has also been a useful test to assess visual function. The gold standard for traditional perimetry is the Humphrey Visual Field Analyzer. Perimetry data is obtained by having the patient look at a fixation target. Stimuli are presented relative to that target with a projector, the light reflects off of the bowl of the instrument and onto the patient’s retina. As long as the patient maintains adequate fixation, the results are very reliable and repeatable. This works quite well for glaucoma patients, as central vision is the last to be affected. In retina patients, we often see just the opposite scenario, the central vision is often the first to be affected. This poses significant problems for standard perimeters. The patient is unable to fixate on the target. The eye begins to search. Once this happens, you cannot assure exactly where you are projecting the stimulus with any degree of certainty. As a result, the perimetry data is questionable at best, useless or misleading at worst.

**Why Microperimetry?**

Microperimetry examination of the macula would be an ideal tool to measure scotoma size, central sensitivity, and fixation behavior in patients with macular disease (Figure 1). The end product of perimetry and microperimetry exams is a sensitivity map of the examined retina. This is obtained by measuring the patient’s ability or inability to perceive light of varying intensities projected on different areas of the retina.

**First Attempts at Microperimetry**

The first instrument to address this need was the Rodenstock Scanning Laser Ophthalmoscope (SLO). The SLO was a very complex machine that in principle and design helped determine the size and location of scotoma and assessed fixation behavior. Unfortunately, although very capable, it was not very reliable. It was very expensive to buy and maintain. It also lacked flexibility and is no longer manufactured.

The MP-1 Microperimeter was developed by a group of European SLO users who wanted a richer feature set as well as color photography.

The MP-1 Microperimeter is a useful adjunct in the diagnosis, treatment and follow-up of patients with macular diseases. It is clinically applicable in evaluating scotomas size, both absolute and relative, studying fixation patterns, and monitoring retinal function. It can also be useful in evaluating macular patients, both preoperatively and postoperatively, and assessing the effectiveness of any macular treatment.
Microperimeter (MP-1)

The MP-1 microperimeter (Figure 4) combines fundus tracking microperimetry with color fundus photography in a single instrument (Figure 5). It was developed by a group of European SLO users who wanted a richer feature set as well as color photography.

The MP-1 initially takes an infrared photograph. The software package allows the operator to select a biological landmark of high reflectivity under infrared i.e., the branch of a retinal vessel.

This image is then digitally registered and matched with the corresponding area on the live video of the patient’s retina. All stimuli are projected directly onto the retina in relation to this landmark, using a LCD. Adjustments for eye movements are made at 25 times per second. This active tracking allows the MP-1 to get reliable perimetry data even when the patient is unable to fixate. If the MP-1 loses tracking, it will stop projecting stimuli until active tracking is re-established. When the exam is complete, a color photograph is taken. A similar registration technique is used to overlay the visual field data over the fundus photo. This makes it easy to correlate the pathology with the scotoma. The MP-1 allows the reporting to be numerically in decibels, schematically or in a color scheme (Figure 6).

This same technology allows the MP-1 to actively track and map the patient’s fixation. There is also a separate fixation exam available that requires less than one minute to perform. This software automatically and accurately maps the location and quality of a patient’s fixation (Figure 7). We are finding fixation analysis to be an invaluable tool to assess the quality of vision and the efficacy of treatment, as well as being prognostic in the efficacy of treatment. We would like to demonstrate the usefulness of the MP-1 in the diagnosis, treatment, and follow-up in some examples of macular diseases.
**Clinical Case Series**

**• Macular Hole/Macular Cyst**

This is a 68-year old woman who presented with a 3 month history of decreasing vision in her right eye (visual acuity 20/80) and mild distortion in her left eye (visual acuity 20/25). She was diagnosed with a macular hole in her right eye and a macular cyst in her left eye. Preoperative fundus photography and ocular coherence tomography (OCT) demonstrated a macular hole in her right eye (Figures 8, 10). Preoperative MP-1 demonstrated a central relative scotoma in an otherwise normal macula (Figure 11). Microperimetry of the left eye with a macular cyst showed normal macular function even though the patient did complain of some mild distortion.

Patient underwent an uncomplicated vitrectomy with successful closure of the macular hole (Figures 9, 12). Although the patient at 3 months stated her vision was markedly improved, her visual acuity had only improved from 20/80 to 20/60. The postoperative MP-1 however showed virtually an elimination of the central scotoma and reestablishment of central fixation explaining her subjective improvement (Figure 13).

**• Subretinal Neovascular Membrane Secondary to Presumed Ocular Histoplasmosis**

This 36-year old female presented with a rapid decrease in vision in her left eye of two weeks’ duration (visual acuity 20/200). Funduscopic evaluation demonstrated a subfoveal subretinal neovascular membrane secondary to presumed ocular histoplasmosis (POHS) (Figure 14). Her preoperative MP-1 demonstrated a significant central dense scotoma with a variable fixation pattern (Figure 15). She underwent a successful treatment with photodynamic therapy and intravitreal triamcinolone. After 3 months the patient returned for follow-up and stated her vision had dramatically improved. However, her visual acuity had improved only from 20/200 to 20/80+. The postoperative fundus photograph demonstrated definite improvement with apparent resolution of serous fluid and hemorrhage (Figure 16). The postoperative MP-1 showed a resolution of the dense scotoma to a relative scotoma and a reestablishment of a strong central fixation explaining her significant subjective improvement (Figure 17).
You can never underestimate the power of corneal, glaucoma and retinal diagnostic solutions. The accuracy, clarity, connectivity, ease of use, resolution, broad applications and the endless possibilities that they bring.

In the growing applications of corneal, glaucoma and retinal diagnostics, NIDEK is well positioned to offer you cutting-edge technologies and state-of-the-art diagnostic solutions for your surgical and patient diagnostic needs. Solutions like the NIDEK NM-200D for non-mydriatic fundus imaging and the NIDEK MP-1 Micro Perimeter, the new standard in retinal diagnostics offers a combination of perimetry and fundus imaging. The NIDEK ConfoScan3 for corneal confocal microscopy and the NIDEK OPD-Scan – offers a leading edging diagnostic platform for your cataract and refractive diagnostic needs. Our on-going commitment to delivering you products that offer you Visionary Performance.
• **Age-related Macular Degeneration with Drusen**

This 78-year old man who had been followed for several years with age-related macular degeneration presented with complaints of decrease in vision in both eyes over the last several weeks. His vision in both eyes had decreased slightly from 20/25 to 20/30. However, the patient was adamant about a significant loss in vision. Fundus photography and fluorescein angiography demonstrated fairly significant drusen in both eyes with central coalescence of drusen into a central large drusen or an early RPE detachment (Figures 18, 19). Microperimetry of both eyes demonstrated that although he was still maintaining a fairly good central fixation, he had developed a dense scotoma associated with the large drusen, possibly explaining his complaints of decreased vision (Figures 20, 21).

![Figure 18: Fluorescein Angiogram - AMD/Drusen](image1)

![Figure 19: Fluorescein Angiogram - AMD/Drusen](image2)

![Figure 20: Microperimetry demonstrating good central fixation but surrounding scotoma.](image3)

![Figure 21: Microperimetry demonstrating good central fixation but surrounding scotoma.](image4)

**Figure 20: Microperimetry demonstrating good central fixation but surrounding scotoma.**

**Figure 21: Microperimetry demonstrating good central fixation but surrounding scotoma.**

• **Age-related Macular Degeneration with mild Atrophic Changes**

This 76-year old man who had been examined previously elsewhere came in for another opinion about his complaints of decrease in vision. He was an attorney and was having significant difficulty reading documents. He had been told that he had very early macular degeneration, but his vision was good and he should not have any trouble. His visual acuity was 20/25+ in both eyes. Funduscopic examination demonstrated mild atrophic changes in the macula with minimal retinal pigment epithelium (RPE) alteration evident on fluorescein angiography. Otherwise, his examination was unremarkable. Microperimetry of both eyes demonstrated a good central fixation behavior (explaining his good visual acuity). However, he did have fairly significant dense scotoma corresponding with the “minimal areas of atrophy” (Figures 22, 23). This could explain his difficulty in reading and following letters. When explained and demonstrated to the patient of his central visual function, he was most relieved to finally have an explanation for his problems. He now uses large magnifiers to read and is quite pleased.

![Figure 22: Central fixation with dense scotoma.](image5)

**Figure 22: Central fixation with dense scotoma.**

![Figure 23: Central fixation with dense scotoma.](image6)

**Figure 23: Central fixation with dense scotoma.**
**Toxic Maculopathies**  
*Plaquenil Toxicity (Early)*

This 36-year-old female had been taking Plaquenil for rheumatoid arthritis for approximately ten years. She had begun to notice an overall decrease in her vision over the past several months. She had been examined elsewhere on several different occasions and had been told her examination was normal. She presented for another opinion. Her visual acuity was 20/20 in both eyes. Funduscopic examination and fluorescein angiography were essentially normal except for very subtle RPE changes noted in the macula in both eyes (Figure 24). The standard perimetry (Humphrey Visual Field) did not show any scotoma or decrease in sensitivity. An MP-1 was performed on both eyes and discovered a significant diffuse decrease in macular sensitivities in both eyes (Figure 25). This was confirmed on repeat testing. The Plaquenil was discontinued. Three months later repeat MP-1 showed a normalization of macular function (Figure 26) and resolution of the patient’s complaints.

**Toxic Maculopathies**  
*Plaquenil Toxicity (Advanced)*

This 48-year-old female had been prescribed Plaquenil for rheumatoid arthritis for the past 15 years. She had been intermittently followed over the last 5 years. She presented with complaints of a significant decrease in vision in both eyes over the last 6 months. Her visual acuity was 20/200 in both eyes. Funduscopic examination and fluorescein angiography demonstrated RPE alteration and the “bull’s-eye” appearance of a toxic maculopathy (Figures 27, 28). MP-1 microperimetry was performed and showed a diffuse dense central scotoma in both eyes (Figure 29). The Plaquenil was discontinued. The patient, however, did not experience any improvement in her visual acuity.

We are now using the MP-1 microperimetry as our primary scanning perimetry for all of our patients on Plaquenil treatment.

**Summary**

These cases are a few examples of how the MP-1 Microperimetry (Nidek) is a useful adjunct in the diagnosis, treatment and follow-up of patients with macular diseases. It is clinically applicable in evaluating scotoma size, both absolute and relative, evaluating fixation patterns, and monitoring retinal function. It can also be useful in evaluating macular patients, both preoperatively and postoperatively, and evaluating the effectiveness of any macular treatment. Locating both the location and size of scotomas in low vision patients can also be very helpful in visual rehabilitation.

We have found the MP-1 useful in dealing with a variety of macular diseases, from determining the effectiveness of PDT treatment in patients with wet macular degeneration to evaluating the possibility of laser treatment in an area of recurrence of a subretinal neovascularization and whether it would affect the patient’s fixation pattern or preferred retinal locus (PRL). From the evaluation of patients with macular dystrophies to macular edema, from macular puckers to macular holes, the MP-1 can be very useful in determining visual function. At present, several prospective studies are on going evaluating the effectiveness of MP-1 in patients following photodynamic therapy treatment, macular hole surgery (with or without membrane peeling) and in patients taking Plaquenil. These studies will hopefully further elucidate the usefulness of this new technology.